Restricted accessResearch articleFirst published online 2026-1
Development and Evaluation of Prednisolone Acetate-Loaded Nanostructured Lipid Carriers Integrated into pH-Triggered In Situ Gels for Ocular Drug Delivery
This study aimed to enhance the therapeutic efficacy of prednisolone by developing a nanostructured lipid carrier (NLC) system for topical ocular administration and addressing the limitations of current topical therapy. Drug-loaded NLCs (prednisolone acetate [PSA1]–PSA13) were formulated using high-pressure homogenization techniques, optimized with a central composite design, and evaluated for various pharmaceutical properties. An optimization study indicates that the lipid ratio and surfactant concentration influence particle size, entrapment efficiency (EE), and drug release. The optimized NLC formulation (PSA3) was integrated into a pH-triggered in situ gel system and assessed for drug permeation, ocular irritation, and stability. The optimized drug-loaded NLC formulations (PSA3) exhibited a nano size of 96.80 ± 0.51 nm, achieving an EE of 84.51 ± 1.31% and a drug release rate of 95.76 ± 1.23%. The drug permeation through the goat cornea was significantly higher in the in situ gel (PSAG4) compared with the control (marketed PSA eye drop). Additionally, the eye irritation data indicated good ocular tolerance, while stability studies confirmed that the developed formulation remained stable at room temperature. In conclusion, the developed NLC-based in situ gel appears to be a promising approach to enhancing the efficacy of prednisolone in topical therapy for the successful treatment of ocular inflammation.
JacobS, NairAB, ShahJ, et al.Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy—An overview on recent advances. Pharmaceutics, 2022; 14(3):533.
2.
LinS, GeC, WangD, et al.Overcoming the anatomical and physiological barriers in topical eye surface medication using a peptide-decorated polymeric micelle. ACS Appl Mater Interfaces, 2019; 11(43):39603–39612.
3.
NairAB, ShahJ, Al-DhubiabBE, et al.Clarithromycin solid lipid nanoparticles for topical ocular therapy: Optimization, evaluation and in vivo studies. Pharmaceutics, 2021; 13(4):523.
4.
AhmedS, AminMM, SayedS. Ocular drug delivery: A comprehensive review. AAPS PharmSciTech, 2023; 24(2):66.
5.
BaigMS, KaradeSK, AhmadA, et al.Lipid-based nanoparticles: Innovations in ocular drug delivery. Front Mol Biosci, 2024; 11:1421959.
6.
Alvarez-TrabadoJ, DieboldY, SanchezA. Designing lipid nanoparticles for topical ocular drug delivery. Int J Pharm, 2017; 532(1):204–217.
7.
BeloquiA, SolinísM, Rodríguez-GascónA, AlmeidaAJ, PréatV. Nanostructured lipid carriers: Promising drug delivery systems for future clinics. Nanomedicine, 2016; 12(1):143–161.
8.
HanH, LiS, XuM, et al.Polymer—and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives. Adv Drug Deliv Rev, 2023; 196:114770.
9.
KambojS, BalaS, NairAB. Solid lipid nanoparticles: An effective lipid-based technology for poorly water-soluble drugs. Int J Pharm Sci Rev Res, 2010; 5:78–90.
10.
YoussefA, DudhipalaN, MajumdarS. Ciprofloxacin loaded nanostructured lipid carriers incorporated into in-situ gels to improve management of bacterial endophthalmitis. Pharmaceutics, 2020; 12(6):572.
11.
GuglevaV, AndonovaV. Recent progress of solid lipid nanoparticles and nanostructured lipid carriers as ocular drug delivery platforms. Pharmaceuticals, 2023; 16(3):474.
12.
HaiderM, AbdinSM, KamalL, OriveG. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics, 2020; 12(3):288.
13.
MallJ, NaseemN, HaiderMF, RahmanMA, KhanS, SiddiquiSN. Nanostructured lipid carriers as a drug delivery system: A comprehensive review with therapeutic applications. Intelligent Pharm, 2024.
14.
GaballaSA, KompellaUB, ElgarhyO, et al.Corticosteroids in ophthalmology: Drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res, 2021; 11(3):866–893.
15.
KumriaR, NairAB, GoomberG, GuptaS. Buccal films of prednisolone with enhanced bioavailability. Drug Deliv, 2016; 23(2):471–478.
16.
NandwaniY, KaurA, BansalAK. Generation of ophthalmic nanosuspension of prednisolone acetate using a novel technology. Pharm Res, 2021; 38(2):319–333.
17.
RathodVR, ShahDA, DaveRH. Systematic implementation of Quality-By-Design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: Preformulation screening studies and statistical hybrid-design for optimization of variables. Drug Dev Ind Pharm, 2020; 46(3):443–455.
18.
PintoF, de BarrosDP, ReisC, FonsecaLP. Optimization of nanostructured lipid carriers loaded with retinoids by central composite design. J Mol Liq, 2019; 293:111468.
19.
YuS, LiQ, LiY, et al.A novel hydrogel with dual temperature and pH responsiveness based on a nanostructured lipid carrier as an ophthalmic delivery system: Enhanced trans-corneal permeability and bioavailability of nepafenac. New J Chem, 2017; 41(10):3920–3929.
20.
SinghAK, KumarM, UpadhyayPK. Nanostructured lipid carriers mediated drug delivery to posterior segment of eye and their in-vivo successes. Curr Pharm Biotechnol, 2024; 25(6):713–723.
21.
YuLX, AmidonG, KhanMA, et al.Understanding pharmaceutical quality by design. Aaps J, 2014; 16(4):771–783.
22.
MladenovicT, ZivicF, PetrovicN, et al.Application of silicone in ophthalmology: A review. Materials (Basel), 2024; 17(14):3454.
23.
PanX, ZhouH, LiZ, et al.Application and safety research of nanotechnology in cosmetics: Current status, challenges, and future prospects. BioNanoSci, 2025; 15(2):284; doi: 10.1007/s12668-025-01884-9
24.
AlMulhimFM, NairAB, AldhubiabB, et al.Design, development, evaluation, and in vivo performance of buccal films embedded with paliperidone-loaded nanostructured lipid carriers. Pharmaceutics, 2023; 15(11):2530.
25.
WuK-W, SweeneyC, DudhipalaN, et al.Primaquine loaded Solid Lipid Nanoparticles (SLN), Nanostructured Lipid Carriers (NLC), and Nanoemulsion (NE): Effect of lipid matrix and surfactant on drug entrapment, in vitro release, and ex vivo hemolysis. AAPS PharmSciTech, 2021; 22(7):240.
26.
KumarM, TiwariA, AsdaqSMB, et al.Itraconazole loaded nano-structured lipid carrier for topical ocular delivery: Optimization and evaluation. Saudi J Biol Sci, 2022; 29(1):1–10.
27.
ShehataTM, NairAB, Al-DhubiabBE, et al.Vesicular emulgel based system for transdermal delivery of insulin: Factorial design and in vivo evaluation. Appl Sci, 2020; 10(15):5341.
28.
BhanderiM, ShahJ, GorainB, et al.Optimized rivastigmine nanoparticles coated with Eudragit for intranasal application to brain delivery: Evaluation and nasal ciliotoxicity studies. Materials (Basel), 2021; 14(21):6291.
29.
MujtabaMA, DesaiH, AmbekarA, et al.Development of chitosan/sodium carboxymethyl cellulose-based polyelectrolyte complex of dexamethasone for treatment of anterior uveitis. Biomed Mater, 2024; 19(6):10.1088/1748–1605X/ad7e6b.
30.
AlhelalHM, MehtaS, KadianV, et al.Solid lipid nanoparticles embedded hydrogels as a promising carrier for retarding irritation of leflunomide. Gels, 2023; 9(7):576.
31.
MorsyMA, NairAB. Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers. Int J Pharm, 2018; 552(1–2):241–250.
32.
DeviS, SainiV, KumarM, BhattS, GuptaS, DeepA. A novel approach of drug localization through development of polymeric micellar system containing azelastine HCl for ocular delivery. Pharm Nanotechnol, 2019; 7(4):314–327.
33.
KouchakM, MahmoodzadehM, FarrahiF. Designing of a pH-triggered Carbopol®/HPMC in situ gel for ocular delivery of dorzolamide HCl: In vitro, in vivo, and ex vivo evaluation. AAPS PharmSciTech, 2019; 20(5):210.
34.
DaveV, PaliwalS, YadavS, SharmaS. Effect of in vitro transcorneal approach of aceclofenac eye drops through excised goat, sheep, and buffalo corneas. Sci World J, 2015; 2015:432376.
35.
GuptaM, MajumdarDK. Effect of concentration, pH, and preservative on in vitro transcorneal permeation of ibuprofen and flurbiprofen from non-buffered aqueous drops. Indian J Exp Biol, 1997; 35(8):844–849.
36.
MalhotraM, MajumdarDK. In vitro transcorneal permeation of ketorolac tromethamine from buffered and unbuffered aqueous ocular drops. Indian J Exp Biol, 1997; 35(9):941–947.
37.
DraizeJH, WoodardG, CalveryHO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther, 1944; 82:377.
38.
ShahJ, NairAB, JacobS, et al.Nanoemulsion based vehicle for effective ocular delivery of moxifloxacin using experimental design and pharmacokinetic study in rabbits. Pharmaceutics, 2019; 11(5):230.
39.
NairAB, ShahJ, JacobS, et al.Experimental design, formulation and in vivo evaluation of a novel topical in situ gel system to treat ocular infections. PLoS One, 2021; 16(3):e0248857.
40.
WilsonSL, AhearneM, HopkinsonA. An overview of current techniques for ocular toxicity testing. Toxicol, 2015; 327:32–46.
41.
ChakrabortyT, GuptaS, NairA, ChauhanS, SainiV. Wound healing potential of insulin-loaded nanoemulsion with Aloe vera gel in diabetic rats. J Drug Deliv Sci Technol, 2021; 64:102637.
42.
CiminoC, Sánchez LópezE, BonaccorsoA, et al.In vitro and in vivo studies of ocular topically administered NLC for the treatment of uveal melanoma. Int J Pharm, 2024; 660:124300.
43.
MoghddamSM, AhadA, AqilM, ImamSS, SultanaY. Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box-Behnken design approach. Artif Cells Nanomed Biotechnol, 2017; 45(3):617–624.
44.
ChauhanM, BegS, KatareOP, SinghB. Nanostructured lipidic carriers for ocular delivery of ofloxacin: Optimization, characterization, and in vivo evaluation. J Drug Target, 2013; 21(7):634–646.
45.
SahooSK, DilnawazF, KrishnakumarS. Nanotechnology in ocular drug delivery. Drug Discov Today, 2008; 13(3–4):144–151.
46.
KhosaA, ReddiS, SahaRN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother, 2018; 103:598–613.
47.
Varela-FernándezR, García-OteroX, Díaz-ToméV, et al.Lactoferrin-loaded Nanostructured Lipid Carriers (NLCs) as a new formulation for optimized ocular drug delivery. Eur J Pharm Biopharm, 2022; 172:144–156.
48.
MatarazzoAP, RiosCA, GerônimoG, OndeiR, de PaulaE, BreitkreitzMC. Development of a versatile Nanostructured Lipid Carrier (NLC) using design of experiments (DoE)—Part II: Incorporation and stability of butamben with different surfactants. Pharmaceutics, 2024; 16(7):863.
49.
PandeS. Factors affecting response variables with emphasis on drug release and loading for optimization of liposomes. Artif Cells Nanomed Biotechnol, 2024; 52(1):334–344.
50.
DhimanN, AwasthiR, SharmaB, KharkwalH, KulkarniGT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem, 2021; 9:580118.
51.
ElmowafyM, Al-SaneaMM. Nanostructured Lipid Carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm J, 2021; 29(9):999–1012.
52.
Leyva-PorrasC, Cruz-AlcantarP, Espinosa-SolísV, et al.Application of Differential Scanning Calorimetry (DSC) and Modulated Differential Scanning Calorimetry (MDSC) in food and drug industries. Polymers (Basel). 2019; 12(1):5.
53.
KaurIP, BhandariR, BhandariS, KakkarV. Potential of solid lipid nanoparticles in brain targeting. J Control Release, 2008; 127(2):97–109.
54.
YoushiaJ, FouadEA, El GazayerlyON. Design of cationic nanostructured lipid carriers for ocular delivery of brimonidine tartrate. J Liposome Res, 2016; 26(2):157–168.
55.
KamelR, AbbasH. PLGA-based monolithic filaments prepared by hot-melt extrusion: In-vitro comparative study. Ann Pharm Fr, 2018; 76(2):97–106.
56.
MohantyD, AlsaidanOA, ZafarA, et al.Development of atomoxetine-loaded NLC in situ gel for nose-to-brain delivery: Optimization, in vitro, and preclinical evaluation. Pharmaceutics, 2023; 15(7):1985.
57.
PathakMK, ChhabraG, PathakK. Design and development of a novel pH-triggered nanoemulsified in-situ ophthalmic gel of fluconazole: Ex-vivo transcorneal permeation, corneal toxicity and irritation testing. Drug Dev Ind Pharm, 2013; 39(5):780–790.
58.
WuY, LiuY, LiX, et al.Research progress of in-situ gelling ophthalmic drug delivery system. Asian J Pharm Sci, 2019; 14(1):1–15.
59.
RanchKM, MaulviFA, NaikMJ, KoliAR, ParikhRK, ShahDO. Optimization of a novel in situ gel for sustained ocular drug delivery using Box–Behnken design: In vitro, ex vivo, in vivo and human studies. Int J Pharm, 2019; 554:264–275.
